Talphera, Inc. (TLPH)
NCM – Real vaqt narxi. Valyuta: USD
0.74
-0.03 (-4.03%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.80
+0.06 (7.88%)
Bozordan keyin: Mar 27, 2026, 6:21 PM EDT

NCM – Real vaqt narxi. Valyuta: USD
0.74
-0.03 (-4.03%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.80
+0.06 (7.88%)
Bozordan keyin: Mar 27, 2026, 6:21 PM EDT
Talphera, Inc., ixtisoslashtirilgan farmatsevtika kompaniyasi, tibbiy nazorat ostida qo'llaniladigan terapiyalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy mahsulot nomzodi Niyad bo'lib, u nafamostatning muzlatib quritilgan shakli bo'lib, u ekstrakorporal davriy davolash uchun antikoagulyant sifatida tadqiqot moslamasi sifatida tekshirilmoqda. Kompaniya shuningdek, LTX-608ni ishlab chiqmoqda, bu nafamostatning to'g'ridan-to'g'ri tomir ichiga yuborish uchun mo'ljallangan formulasi bo'lib, u virusga qarshi, o'tkir respirator distress sindromi, tarqalgan intrakorpusulyar koagulyatsiya va o'tkir pankreatit kabi turli ko'rsatkichlar uchun tadqiqot mahsuloti hisoblanadi, shuningdek, tayyor Fedsyra va fenilefrinli oldindan to'ldirilgan shprits nomzodlari. Kompaniya ilgari AcelRx Pharmaceuticals, Inc. nomi bilan tanilgan va 2024 yil yanvar oyida Talphera, Inc. deb nomini o'zgartirgan. Kompaniya 2005 yilda tashkil etilgan va San-Mateo, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
| Mr. Anil N. Dasu | Chief Engineering Officer |
| Mr. Raffi Mark Asadorian | Chief Financial Officer |
| Mr. Vincent J. Angotti | CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-16 | 8-K | acrx20260316_8k.htm |
| 2026-03-13 | 8-K | acrx20260313_8k.htm |
| 2025-11-12 | 10-Q | acrx20250930_10q.htm |
| 2025-10-28 | S-3 | acrx20251027_s3.htm |
| 2025-10-24 | 8-K | acrx20251023_8k.htm |
| 2025-10-22 | 8-K | acrx20251021_8k.htm |
| 2025-10-16 | 8-K | acrx20251015_8k.htm |
| 2025-09-25 | CORRESP | filename1.htm |
| 2025-09-24 | ARS | talphera_ars.pdf |
| 2025-09-22 | S-3 | acrx20250919_s3.htm |